|
2023
|
Invention
|
Nrf2 protein degraders. The present disclosure provides compounds represented by Formula A-I: and... |
|
2022
|
Invention
|
Combination therapy with a don prodrug and a tigit inhibitor. The present disclosure provides the... |
|
2021
|
Invention
|
Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)... |
|
|
Invention
|
Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido... |
|
2020
|
Invention
|
Method of preparing a don prodrug from l-glutamic acid. 3 are as defined as set forth in the appl... |
|
|
Invention
|
Method of preparing a don prodrug from l-pyroglutamic acid. The present disclosure provides a met... |
|
|
Invention
|
Method of preparing a don prodrug from l-glutamic acid. The present disclosure provides methods o... |
|
|
Invention
|
Combinaton therapy with a don prodrug and an immune checkpoint inhibitor.
The present disclosure... |
|
|
Invention
|
Combinaton therapy with a don prodrug and an immune checkpoint inhibitor. The present disclosure ... |
|
|
Invention
|
Method of preparing a don prodrug from l-pyroglutamic acid. 6 alkyl, (aryl)alkyl, and (heteroaryl... |
